6533b7d1fe1ef96bd125d859

RESEARCH PRODUCT

Donors with KIR-Bx Haplotypes Improve Outcome of Unrelated Hematopoietic Stem Cell Transplantation for Recipients with a Myeloid Malignant Disease and a C1 Ligand Phenotype

Micheal PfreundschuhJoannis MytilineosDonald BunjesRenate ArnoldCarlheinz MüllerChristine ZollikoferBertram GlassHubert SchrezenmeierHermann EinseleDaniel E. FurstGernot StuhlerGerald WulfDietger NiederwieserEva WagnerMartin Gramatzki

subject

OncologyChemotherapymedicine.medical_specialtyTransplantationMyeloidbusiness.industrymedicine.medical_treatmentHaplotypeHematopoietic stem cell transplantationTransplant-Related MortalityHematologyLigand (biochemistry)Phenotype3. Good healthmedicine.anatomical_structureInternal medicinemedicineBone marrowbusiness

description

relapse, or transplant related mortality (TRM) (p1⁄40.2, p1⁄40.1, p1⁄40.08, respectively). To investigate why higher CPSS scores were associated with higher mortality, we performed analysis restricted to patients with relapse following HCT. Those with intermediate-2/high riskhadnearly two-fold increase in riskof death after relapse compared to thosewith low/intermediate1 CPSS scores. Corresponding rates for low/intermediate-1 risk groups,OSat1year, 3years, and5yearswere61%,48%, and44% respectivelyand for intermediate-2/high riskgroupswere 38%, 32%, and19%respectively.OSofpatientswho receivedpre-HCT treatment with hypomethylating agents, chemotherapy, or both was not different compared to those who received no therapy prior (p1⁄40.96). In summary, CPSS scores, lower KPS scores, and bone marrow as graft source were associated with poorer outcomes following HCT.

10.1016/j.bbmt.2014.11.023http://dx.doi.org/10.1016/j.bbmt.2014.11.023